ArticleScientific reports2025
A novel chromen-based small molecule induces apoptosis and modulates cellular response to triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is challenging to treat due to its aggressive nature. Its lack of hormone receptors renders conventional therapies less effective. This study assessed the efficacy of a novel compound, compound 2, in modulating TNBC cell behaviour. We used in vitro assays with MDA-MB-468 and MDA-MB-231 cell lines. Methods included annexin V apoptosis assay, flow cytometry for cell cycle and qRT-PCR for gene expression. Clonogenic, adhesion and wound healing assays were used for phenotypic characterization. Cytokine and chemokine levels in MDA-MB-468 cells were also measured using a Luminex assay. Compound 2 increased both early and late apoptosis in cancer cells, particularly MDA MB 468 cells. It also upregulated pro-apoptotic genes while downregulating anti-apoptotic genes. Additionally, it induced G1-phase arrest in MDA MB 468 cells with downregulation in Ki67 expression. Compound 2 also reduced cancer stem cell populations, suppressed colony formation, and impaired cell migration at IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.